Program
iloperidone
Also written as “Iloperidone”, “Iloperidone 1 MG” and “iloperidone (oral tablet)”.
Its studies are mostly in Schizophrenia · Hypertension · Parkinson Disease, led by 4 companies.
Drug pageIloperidone: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticalsits history only | 103 open or running | phase 4since Dec 5, 2022 | Nov 10, 2005 | Nov 2027phase 3 · NCT06961968 |
| CSPC Pharmaceutical Groupits history only | 20 open or running | phase 3since May 19, 2015 | May 19, 2015 | none ahead |
| Novartis | 20 open or running | phase 4since Sep 19, 2010 | Sep 19, 2010 | none ahead |
| Hansoh Pharmaceutical Groupits history only | 10 open or running | phase 2since Jun 17, 2012 | Jun 17, 2012 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 19, 2010First study: phase 4 study in SchizophreniaFirst studyNCT01207414 · 501 enrolled · United States
- Sep 23, 2011Phase 1 study in Hepatic ImpairmentNCT01529294 · 90 enrolled · United States
TargetBeta
“Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Aripiprazolerule | Otsuka | phase 4 | 131 |
| Risperidonerule | Johnson & Johnson | phase 4 | 111 |
| paliperidonerule | Johnson & Johnson | phase 4 | 106 |
| Olanzapinerule | Eli Lilly | phase 4 | 76 |
| brexpiprazolerule | Otsuka | phase 4 | 70 |
| lurasidonerule | Sumitomo Pharma | phase 4 | 52 |
| lumateperonerule | Johnson & Johnson | phase 3 | 25 |
Studies
All 2 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01529294Hepatic Impairment · United States | 1 | Completed | Jul 2012 | 90 |
| NCT01207414Schizophrenia · United States | 4 | Completed | Jan 2012 | 501 |
How it is read
Names in the registry
- “Iloperidone”, 9 entries
- “iloperidone”, 4 entries
- “Iloperidone 1 MG”, 1 entry
- “iloperidone (oral tablet)”, 1 entry
Conditions, from the studies’ own filings
- Schizophrenia, 10 studies
- Hypertension, 1 study
- Parkinson Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.